Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity

Maike Marleen Holtsche, Nina Van Beek, Takashi Hashimoto, Giovanni Di Zenzo, Detlef Zillikens, Catherine Prost-Squarcioni, Matthias Titeux, Alain Hovnanian, Enno Schmidt, Stephanie Goletz*

*Corresponding author for this work

Abstract

Epidermolysis bullosa acquisita is a pemphigoid disease characterized by autoantibodies against type VII collagen. This study compared the sensitivity and specificity of 6 diagnostic assays: type VII collagen noncollagenous domains enzyme-linked immunoassay (NC1/2 ELISA) (MBL, Nagoya, Japan); type VII collagen NC1 ELISA (Euroimmun, Lübeck, Germany); indirect immunofluorescence (IF) microscopy test based on the expression of recombinant NC1 in a human cell line (NC1 BIOCHIP®; Euroimmun); full-length recombinant type VII collagen ELISA; immunoblotting with full-length type VII collagen in the extract of human dermis; and immunoblotting with recombinant NC1. Immunoblotting with recombinant NC1 showed a sensitivity of 93.1% and specificity of 100%, followed by NC1 BIOCHIP® (sensitivity, 89.1%; specificity, 100%), immunoblotting with human dermis (sensitivity, 87.1%; specificity 100%), NC1-ELISA (sensitivity 82.2%; specificity 98.6%), NC1/NC2 ELISA (sensitivity 88.1%; specificity 93.3%), and full-length type VII collagen ELISA (sensitivity 80.2%; specificity 93.8%).

Original languageEnglish
Article numberadv00420
JournalActa Dermato-Venereologica
Volume101
Issue number3
Pages (from-to)adv00420
ISSN0001-5555
DOIs
Publication statusPublished - 2021

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Fingerprint

Dive into the research topics of 'Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity'. Together they form a unique fingerprint.

Cite this